Detection of circulating tumor DNA (ctDNA) has recently emerged as an alternative to EGFR mutation testing, but plasma ctDNA mutation detection can be easily affected by tumor burden and has a relatively high false-negative rate (14). This evidence concerns the gene EGFR and neoplasm.